Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Atara Biotherapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 91
- −17 vs. Q3 2023
- Shares held
- 64.7M
- −22.5M (−25.8%) vs. Q3 2023
- Total value
- $33.2M
- −$95.8M (−74.3%) vs. Q3 2023
- New holders
- 18
- 29 more added
- Sold out
- 35
- 33 more reduced
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ATRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 36 | $51.3M |
| Q1 2026 | 33 | $12.1M |
| Q4 2025 | 41 | $37.1M |
| Q3 2025 | 37 | $27.0M |
| Q2 2025 | 32 | $13.9M |
| Q1 2025 | 37 | $12.4M |
| Q4 2024 | 43 | $31.5M |
| Q3 2024 | 35 | $19.6M |
| Q2 2024 | 48 | $24.1M |
| Q1 2024 | 82 | $57.8M |
| Q4 2023 | 91 | $33.2M |
| Q3 2023 | 109 | $130.5M |
| Q2 2023 | 118 | $145.8M |
| Q1 2023 | 125 | $297.8M |
| Q4 2022 | 139 | $319.3M |
| Q3 2022 | 155 | $376.2M |
| Q2 2022 | 134 | $777.4M |
| Q1 2022 | 145 | $909.5M |
| Q4 2021 | 139 | $1.50B |
| Q3 2021 | 140 | $1.61B |
| Q2 2021 | 145 | $1.34B |
| Q1 2021 | 151 | $1.24B |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Atara Biotherapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Arctis Global LLC | 0 | $0 | 0.00% | −397,046−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −219,462−100.0% | Sold out |
| Josh Arnold Investment Consultant, LLC | 0 | $0 | 0.00% | −200,000−100.0% | Sold out |
| Nuveen Asset Management, LLC | 0 | $0 | 0.00% | −132,865−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −118,193−100.0% | Sold out |
| Cornercap Investment Counsel Inc | 0 | $0 | 0.00% | −114,697−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −62,017−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −49,730−100.0% | Sold out |
| B. Metzler seel. Sohn & Co. AG | 0 | $0 | 0.00% | −49,282−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −38,967−100.0% | Sold out |
| Belvedere Trading LLC | 0 | $0 | 0.00% | −37,239−100.0% | Sold out |
| JustInvest LLC | 0 | $0 | 0.00% | −34,366−100.0% | Sold out |
| SEI Investments Co | 0 | $0 | 0.00% | −32,204−100.0% | Sold out |
| Oppenheimer & Co Inc | 0 | $0 | 0.00% | −16,646−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −11,927−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −10,555−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −7,126−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −5,162−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −3,000−100.0% | Sold out |
| China Universal Asset Management Co., Ltd. | 0 | $0 | 0.00% | −2,588−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −2,400−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −1,767−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −153−100.0% | Sold out |
| Comerica Bank | 0 | $0 | 0.00% | −108−100.0% | Sold out |
| Cary Street Partner Investment Advisory LLC | 0 | $0 | 0.00% | −66−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −290−100.0% | Sold out |
| Antipodean Advisors LLC | – | – | – | – | Not filed |